ViiV Healthcare, a GlaxoSmithKline subsidiary, announced that the FDA has granted its injectable cabotegravir breakthrough therapy designation to prevent HIV. The status was granted based on data from a Phase IIb/III trial that showed cabotegravir being 66% more effective than the oral combo of emtricitabine, tenofovir disoproxil fumarate for HIV prevention.